INVESTIGATION OF HERITAGE BURDEN AS A RISK FACTOR FOR DEVELOPMENT OF LUNG CARCINOMA

Tanyo Stefanov

Abstract


The article presents a study of hereditary burden as a risk factor for the development of lung cancer. Direct relatives diagnosed with cancer were found in 5.92% of the respondents. 7.65% said they were not sure, which makes it likely that the above percentage would be higher. In tracking the presence of direct relatives of lung cancer, we found one in 3.33% of the participants in our study.

Keywords


hereditary burden, lung, carcinoma

Full Text:

PDF

References


Harris RE, Beebe-Donk J et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005 Apr;13(4):559-83.

Heimburger DC, Alexander CB et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA. 1988 Mar 11;259(10):1525-30.

Jemal A, Siegel R et al. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar;56(2):106-30.

Kleinerman RA, Tarone RE et al. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst. 2000 Dec 20;92(24):2037-9.

Knekt P, Jarvinen R, et al. Role of various carotenoids in lung cancer prevention. J Natl Cancer Inst. 1999 Jan 20;91(2):182-4.

Kolonel LN. Lung cancer: Another consequence of a high-fat diet? J Natl Cancer Inst. 1993 Dec 1;85(23):1886-7.

Miller YE. Pathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol. 2005 Sep;33(3):216-23

Minna JD. Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer. J Clin Invest. 2003 Jan;111(1):31-3.

Nesbitt JC, Putnam JB Jr et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995 Aug;60(2):466-72.

Raez L, Samuels M et al. Combined modality therapy for limited-disease small cell lung cancer. Curr Treat Options Oncol. 2005 Jan;6(1):69-74.

Rostad H, Naalsund A et al. Small cell lung cancer in Norway: Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg. 2004 Oct;26(4):782-6.

Rosti G, Bvilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G. Small cell lung cancer. Ann Oncol, England; Vol 17 Suppl 2, No (4/13/2006): pp. ii5-ii10

Scagliotti GV, Novello S. Adjuvant therapy in completely resected non-small-cell lung cancer. Curr Oncol Rep. 2003 Jul;5(4):318-25.

Silvano G. New radiation techniques for treatment of locally advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2006 Mar;17 Suppl 2:ii34-ii35.

Toyooka S, Pass HI et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res. 2001 Aug 1;61(15):5727-30.

Waddell TK, Shepherd FA. Should aggressive surgery ever be part of the management of small cell lung cancer? Thorac Surg Clin. 2004 May;14(2):271-81.

Winton T, Livingston R et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23;352(25):2589-97.

World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.3. ISBN 92-832-0429-8.

Bond-Smith, G; Banga, N; Hammond, TM; Imber, CJ (May 16, 2012). Pancreatic adenocarcinoma. BMJ (Clinical research ed.). 344: e2476. doi:10.1136/bmj.e2476. PMID 22592847.

World Cancer Report 2014. World Health Organization. 2014. pp. 473–474. ISBN 92-832-0429-8.

Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 (invasive) and Table 3 (in situ) from Eheman CR, Shaw KM, Ryerson AB.


Refbacks

  • There are currently no refbacks.


New knowledge Journal of science Jubilee edition is financed by the National Science Fund of the Republic of Bulgaria – contract № ДНП 05/52 от 22.12.2016 in the competition of Bulgarian scientific periodicals – 2016

The contents of this publication do not necessarily reflect the position or opinion of the National Science Fund of the Republic of Bulgaria. The opinions expressed are those of the author(s) only and should not be considered as representative of the National Science Fund’s official position.

https://www.fni.bg/

National Science Fund of Bulgaria